Rosuvastatin surpasses atorvastatin across full dose range

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1359, 2002-01, pp. : 7-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Aleglitazar, a balanced PPARα/γ agonist, has no clinically relevant pharmacokinetic interaction with high-dose atorvastatin or rosuvastatin

By Foley-Comer Adam J   Young Anne-Marie   Russell-Yarde Fiona   Jordan Paul  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 1, 2011-01 ,pp. : 3-12

Informa Healthcare

Access to resources Recommend Favorite

Effects of Low-Dose Atorvastatin and Rosuvastatin on Plasma Lipid Profiles: A Long-Term, Randomized, Open-Label Study in Patients with Primary Hypercholesterolemia

By Mazza Fabio   Stefanutti Claudia   Serafina Di Giacomo   Vivenzio Antonio   Fraone Nadia   Mazzarella Bruno   Bucci Antonello  

American Journal of Cardiovascular Drugs, Vol. 8, Iss. 4, 2008-01 ,pp. : 265-270

Adis International

Access to resources Recommend Favorite

AstraZeneca's rosuvastatin up against Pfizer's atorvastatin in the US

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 426, 2003-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Ezetimibe + low-dose atorvastatin vs high-dose atorvastatin

By  

Inpharma, Vol. 1, Iss. 1580, 2007-01 ,pp. : 20-20

Adis International

Access to resources Recommend Favorite

Rosuvastatin well tolerated by a broad range of patients

By  

Reactions Weekly, Vol. 1, Iss. 1029, 2004-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite